SIRPA Gene
Overview
SIRPA (signal regulatory protein alpha), also known as PTPNS1 (protein tyrosine phosphatase, non-receptor type substrate 1), is a transmembrane glycoprotein encoded by the SIRPA gene located on chromosome 20p13 in humans. This immunoglobulin superfamily member functions as a key regulator of innate immune signaling and has emerged as an important player in neuroinflammatory processes associated with neurodegeneration. SIRPA is expressed on the surface of macrophages, dendritic cells, and other myeloid cells, where it serves as a critical "don't eat me" signal and regulator of phagocytic activity. The protein's role in controlling microglial activation and neuroinflammation has positioned it as a molecule of significant interest in understanding how immune dysregulation contributes to neurodegenerative disease pathology.
Function/Biology
SIRPA functions primarily as a receptor that transduces inhibitory signals when engaged by its ligand, CD47, expressed on healthy cells. The protein consists of an extracellular region containing three immunoglobulin-like domains, a transmembrane domain, and an intracellular region containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). When CD47 on cell surfaces binds to SIRPA on immune cells, it triggers recruitment of the protein tyrosine phosphatase SHP-1 (PTPN6) and SHP-2 (PTPN11) to the cytoplasmic tail, resulting in dephosphorylation of downstream signaling molecules and suppression of immune activation.
...SIRPA Gene
Overview
SIRPA (signal regulatory protein alpha), also known as PTPNS1 (protein tyrosine phosphatase, non-receptor type substrate 1), is a transmembrane glycoprotein encoded by the SIRPA gene located on chromosome 20p13 in humans. This immunoglobulin superfamily member functions as a key regulator of innate immune signaling and has emerged as an important player in neuroinflammatory processes associated with neurodegeneration. SIRPA is expressed on the surface of macrophages, dendritic cells, and other myeloid cells, where it serves as a critical "don't eat me" signal and regulator of phagocytic activity. The protein's role in controlling microglial activation and neuroinflammation has positioned it as a molecule of significant interest in understanding how immune dysregulation contributes to neurodegenerative disease pathology.
Function/Biology
SIRPA functions primarily as a receptor that transduces inhibitory signals when engaged by its ligand, CD47, expressed on healthy cells. The protein consists of an extracellular region containing three immunoglobulin-like domains, a transmembrane domain, and an intracellular region containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). When CD47 on cell surfaces binds to SIRPA on immune cells, it triggers recruitment of the protein tyrosine phosphatase SHP-1 (PTPN6) and SHP-2 (PTPN11) to the cytoplasmic tail, resulting in dephosphorylation of downstream signaling molecules and suppression of immune activation.
In the central nervous system, SIRPA is highly expressed on microglia, the resident immune cells of the brain and spinal cord. Under physiological conditions, SIRPA-CD47 interactions help maintain microglial homeostasis and prevent excessive immune activation. This interaction is critical for limiting microglial-mediated phagocytosis of viable neurons and synapses. The SIRPA signaling pathway also influences cytokine production, reactive oxygen species generation, and overall microglial polarization toward either pro-inflammatory or anti-inflammatory phenotypes.
Role in Neurodegeneration
SIRPA dysfunction has been implicated in multiple neurodegenerative conditions through alterations in microglial behavior and neuroinflammatory balance. In Alzheimer's disease, dysregulation of SIRPA-CD47 signaling contributes to enhanced microglial activation and increased phagocytosis of synapses and viable neurons, a process termed "synaptic pruning." Genetic variations affecting SIRPA expression or function may impair the capacity of microglia to distinguish between pathological and healthy neuronal elements, leading to excessive neuronal loss independent of direct amyloid or tau pathology.
In Parkinson's disease, altered SIRPA signaling has been associated with enhanced microglial activation in response to alpha-synuclein accumulation. The loss of SIRPA-mediated inhibitory signaling permits excessive phagocytosis and inflammatory cytokine release, amplifying neuronal damage to dopaminergic neurons. Similarly, in amyotrophic lateral sclerosis (ALS), microglial SIRPA expression appears to be downregulated in disease states, contributing to the progressive neuroinflammatory cascade that characterizes the condition.
Molecular Mechanisms
The molecular mechanisms through which SIRPA dysfunction promotes neurodegeneration involve several interconnected pathways. Loss of SIRPA inhibitory signaling leads to activation of Src family kinases and downstream signaling cascades including phospholipase C-gamma (PLCγ) and mitogen-activated protein kinase (MAPK) pathways. This results in increased production of pro-inflammatory mediators including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β).
Additionally, SIRPA dysfunction affects the balance between pro-inflammatory M1 microglial polarization and anti-inflammatory M2 polarization. Enhanced SIRPA signaling promotes M2 polarization and neuroprotective phenotypes, while SIRPA loss favors M1 activation associated with neurotoxicity. The protein also regulates complement receptor expression and the phagocytic capacity of microglia, directly influencing how efficiently these cells engulf amyloid-beta, tau tangles, and other pathological substrates.
Clinical/Research Significance
SIRPA has become a therapeutic target of interest for neurodegeneration. CD47-mimetic peptides and blocking antibodies targeting SIRPA are being investigated to modulate microglial activity. Conversely, enhancing SIRPA signaling through CD47-Fc fusion proteins represents an alternative therapeutic strategy. Understanding SIRPA polymorphisms and their association with neurodegenerative disease risk may facilitate development of biomarkers for disease susceptibility and progression.
- CD47 - Primary ligand of SIRPA; expressed on neuronal surfaces
- SHP-1/SHP-2 - Protein tyrosine phosphatases recruited by SIRPA
- Microglia - Primary CNS cells expressing SIRPA
- Neuroinflammation - Broader
Pathway Diagram
The following diagram shows the key molecular relationships involving SIRPA Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)